Specific Antibody Deficiency: When Prophylaxis Stops Being Enough
A seven-year-old with normal immunoglobulin levels keeps getting sinus infections anyway, because his antibodies can't hold onto the shape of a polysaccharide vaccine. The real disagreement is where the line sits between watching, prophylaxis, and a trial of immunoglobulin replacement itself.
Oliver K. is the goalkeeper for his second-grade soccer team, a position his coach picked specifically because he's the one kid on the roster who doesn't seem to mind standing still for long stretches between plays — useful, since three sinus infections since September have kept him out of more games than he's played in. He is otherwise a healthy, previously unremarkable child, born full-term with no prior chronic diagnoses, and his older sister has no history of recurrent infections at all. His total IgG, IgA, and IgM have all been normal on repeated testing, along with normal IgG subclasses, which is exactly what made the diagnosis take longer than his parents expected: nothing about his baseline antibody numbers looked abnormal until his immunologist specifically tested his response to the pneumococcal polysaccharide vaccine and found it markedly blunted — protective titers to only three of the fourteen serotypes tested, well below what a healthy seven-year-old should mount.
That finding — normal antibody quantity, genuinely impaired antibody function against polysaccharide antigens specifically — defines specific antibody deficiency, and Perez, Bonilla, Orange, and Ballow's 2017 review in Frontiers in Immunology is explicit that the condition spans a real severity spectrum with no settled answer for where prophylaxis stops being enough. He was started on daily amoxicillin prophylaxis five months ago, following the Bonilla et al. 2015 Joint Task Force practice parameter's standard first step, and has still had one sinus infection requiring a second antibiotic course since starting it — not a dramatic failure, but not the quiet stability his family was hoping prophylaxis would deliver either. His weight and height have continued along their own established curves throughout, and he has shown no signs of the recurrent skin, gastrointestinal, or systemic infections that would point toward a more severe underlying antibody deficiency than the one already identified.
Naming what would actually count as failure
He's already had a breakthrough infection on prophylaxis. Specific antibody deficiency is a genuine spectrum — Perez, Bonilla, Orange, and Ballow describe children who function much closer to a treatable antibody deficiency than to ordinary recurrent childhood infections, and his own polysaccharide response, three of fourteen serotypes, sits well into that impaired range. I want to move to a defined trial of immunoglobulin replacement.
One breakthrough infection in five months on a first-line prophylaxis isn't necessarily prophylaxis failing — it might be an incompletely optimized dose, or just an ordinary infection any seven-year-old could get. Immunoglobulin replacement means monthly infusions or weekly injections for a child who is otherwise growing and developing entirely normally; that's a real burden to commit him to.
Calling three of fourteen serotypes "impaired" is accurate, but it doesn't by itself tell us he's failing prophylaxis — it tells us why he was diagnosed, not what his actual trajectory on treatment will be.
The disagreement here is really about what counts as failure, and nobody wrote that down before starting amoxicillin five months ago. Let's set it explicitly now: confirm he's on a weight-appropriate prophylactic dose, and agree in advance that two more breakthrough infections requiring antibiotics within the next six months, documented and dated, moves us to a defined three-month trial of immunoglobulin replacement with explicit stop criteria if it isn't clearly reducing his infection frequency. That way the next decision doesn't get relitigated from scratch after the next infection.
Amoxicillin dosing was confirmed appropriate for his current weight, and the written two-infection threshold for an immunoglobulin trial was documented in his chart with an explicit three-month trial length and stop criteria if his infection frequency doesn't clearly improve.
Agreed by all three, and treated as the actual resolution of the disagreement: whatever position each specialist started from, having an explicit written threshold removes the argument from the next visit, whichever way his infections go between now and then.